Peter Gruss
Chief Executive Officer chez Okinawa Kagaku Gijutsu Daigakuin Daigaku Gakuen Educational
Profil
Peter Gruss is the founder of DeveloGen AG, which was founded in 1997.
He currently holds several positions, including President & Chief Executive Officer at Okinawa Kagaku Gijutsu Daigakuin Daigaku Gakuen Educational, Member at Deutsche Forschungsgemeinschaft, Member at Deutsche Akademie der Naturforscher Leopoldina eV, Member at Deutsche Akademie der Technikwissenschaften eV, and Trustee at Max Planck Florida Institute for Neuroscience.
In the past, he has worked as an Independent Non-Executive Director at Actelion Ltd., Director at The Francis Crick Institute Ltd., Director at Max Planck Institute For Biophysical Chemistry, Member-Supervisory Board at Münchener Rückversicherungs-Gesellschaft AG, Member-Supervisory Board at Siemens AG, Professor at Ruprecht-Karls-Universität Heidelberg, and Assistant-Institute for Virus Research at German Cancer Research Center.
He has an undergraduate degree from Technische Universität Darmstadt and a doctorate degree from Ruprecht-Karls-Universität Heidelberg.
Postes actifs de Peter Gruss
| Sociétés | Poste | Début |
|---|---|---|
| Deutsche Forschungsgemeinschaft | Corporate Officer/Principal | - |
Deutsche Akademie der Technikwissenschaften eV
 Deutsche Akademie der Technikwissenschaften eV Miscellaneous Commercial ServicesCommercial Services Deutsche Akademie der Technikwissenschaften eV advises on technical and technological issues for engineering and applied sciences. The private company is based in Munich, Germany. | Corporate Officer/Principal | - |
| Deutsche Akademie der Naturforscher Leopoldina eV | Corporate Officer/Principal | - |
| Okinawa Kagaku Gijutsu Daigakuin Daigaku Gakuen Educational | Chief Executive Officer | 01/01/2017 |
Max Planck Florida Institute for Neuroscience
 Max Planck Florida Institute for Neuroscience Miscellaneous Commercial ServicesCommercial Services Max Planck Florida Institute for Neuroscience provides research services. It offers its services for neurobiology, brain function, neural circuits, neurological disorders, synaptic networks and bio-imaging. The company was founded in 2008 and is headquartered in Jupiter, FL. | Director/Board Member | - |
Anciens postes connus de Peter Gruss
| Sociétés | Poste | Fin |
|---|---|---|
| MUNICH RE | Director/Board Member | 30/06/2017 |
| ACTELION | Director/Board Member | 16/06/2017 |
| SIEMENS AG | Director/Board Member | 27/01/2015 |
| Ruprecht-Karls-Universität Heidelberg | Corporate Officer/Principal | 01/01/1986 |
| ░░░░░░ ░░░░░░ ░░░░░░░░ ░░░░░░ | ░░░░░░░░░ ░░░░░░░░░░░░░░░░░ | - |
Formation de Peter Gruss
| Technische Universität Darmstadt | Undergraduate Degree |
| Ruprecht-Karls-Universität Heidelberg | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 2 |
|---|---|
| MUNICH RE | Finance |
| SIEMENS AG | Producer Manufacturing |
| Entreprise privées | 8 |
|---|---|
Actelion Ltd.
 Actelion Ltd. Pharmaceuticals: MajorHealth Technology Actelion Ltd. develops, produces and markets pharmaceutical drugs. The firm engages in research, development, manufacturing, and distribution of pharmaceutical, biological, and diagnostic products. The company was founded by Jean-Paul Clozel, Martine Clozel, Walter Fischli, André J. Müller and Thomas Widmann on December 30, 1999 and is headquartered in Allschwil, Switzerland. | Health Technology |
DeveloGen AG
 DeveloGen AG Pharmaceuticals: MajorHealth Technology DeveloGen AG is a biopharmaceutical company engaged in the discovery and development of novel therapeutics for the treatment of metabolic and endocrine disorders with a particular focus on diabetes. DeveloGen develops highly innovative approaches for the treatment of diabetes and obesity targeting key pathophysiological mechanisms such as insulin resistance and loss of insulin-producing beta cells. DeveloGen's product pipeline includes two programs at advanced stages of lead optimization, a small molecule inhibitor program based on a novel and proprietary target to address insulin resistance (type 2 diabetes). A growth factor targeting beta cell regeneration (type 1 and type 2 diabetes). DeveloGen is based in Goettingen, Germany. | Health Technology |
Max Planck Gesellschaft zur Förderung der Wissenschaften eV
 Max Planck Gesellschaft zur Förderung der Wissenschaften eV Investment Trusts/Mutual FundsMiscellaneous Max Planck Gesellschaft zur Förderung der Wissenschaften eV (MPG) is a non-profit organization headquartered in Munich, Germany. The firm was founded in 1948 as a successor organization to the Kaiser Wilhelm Society. MPG conducts basic research in the natural sciences, life sciences, and humanities and provides investment advisory services to foundations. | Miscellaneous |
German Cancer Research Center
 German Cancer Research Center Hospital/Nursing ManagementHealth Services German Cancer Research Center offers biomedical research services. It develops novel approaches to make tumor diagnosis more precise and for a treatment of cancer. The firm provides different research programs such as cell and tumor biology, functional and structural genomics, risk factors and prevention, tumor immunology, imaging and radio oncology, and translational cancer research. The company was founded in 1964 and is headquartered in Heidelberg, Germany. | Health Services |
| Deutsche Akademie der Naturforscher Leopoldina eV | |
Deutsche Akademie der Technikwissenschaften eV
Deutsche Akademie der Technikwissenschaften eV Miscellaneous Commercial ServicesCommercial Services Deutsche Akademie der Technikwissenschaften eV advises on technical and technological issues for engineering and applied sciences. The private company is based in Munich, Germany. | Commercial Services |
The Francis Crick Institute Ltd.
 The Francis Crick Institute Ltd. Medical/Nursing ServicesHealth Services The Francis Crick Institute Ltd. operates as a biomedical discovery institute dedicated to understanding the scientific mechanisms of living things. The firms works helps to understand why disease develops and to find new ways to treat, diagnose, and prevent illnesses such as cancer, heart disease, stroke, infections, and neurodegenerative diseases. The company is headquartered in London, the United Kingdom. | Health Services |
Max Planck Florida Institute for Neuroscience
Max Planck Florida Institute for Neuroscience Miscellaneous Commercial ServicesCommercial Services Max Planck Florida Institute for Neuroscience provides research services. It offers its services for neurobiology, brain function, neural circuits, neurological disorders, synaptic networks and bio-imaging. The company was founded in 2008 and is headquartered in Jupiter, FL. | Commercial Services |
